Side-by-side research comparison of Cagrilintide and Semaglutide across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. No direct head-to-head trials in our corpus — this comparison synthesizes indirect evidence across 53 Cagrilintide studies and 662 Semaglutide studies.
| Cagrilintide | Semaglutide | |
|---|---|---|
| Drug class | amylin agonist | glp 1 agonist |
| Studies in corpus | 53 | 662 |
| Highest evidence tier | rct | — |
| Evidence tier mix | rct · 28 other · 7 review · 3 | n/a |
| Studies with explicit sample size | 12 | 0 |
| Head-to-head studies in corpus | 0 — indirect comparison only | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Cagrilintide and Semaglutide batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 1468 Cagrilintide batches across 504 manufacturers, 99.54% avg purity.
We tested 2418 Semaglutide batches across 608 manufacturers, 99.66% avg purity.
We hold deeper lab coverage on Semaglutide (2418 batches tested). Semaglutide edges ahead on average measured purity (99.54% vs 99.66%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Looking for vendor-level purity, endotoxin, and HPLC data on Cagrilintide or Semaglutide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.